Clinical Trials Logo

Clinical Trial Summary

The present study will randomize 50 symptomatic heart failure patients with severely reduced left ventricular ejection fraction (LVEF) and a true left bundle branch block to either direct HIS-pacing or biventricular pacing and follow them for at least six months. The outcome is how often it is possible to achieve HIS-pacing at implant and during follow-up and if HIS-pacing leads to differences in symptoms or measurable clinical parameters as compared to biventricular pacing.

Clinical Trial Description

Biventricular (BiV) pacing is an established treatment of symptomatic heart failure patients with severely reduced left ventricular ejection fraction (HFrEF) and wide QRS due to bundle branch block (BBB) on a 12-lead ECG. BiV pacing is normally achieved with an endocardial pacing lead in the right ventricle and an epicardial lead over the left ventricle situated in a coronary vein. BiV pacing does not correct the BBB but corrects the mechanical dyssynchrony that is a consequence of the BBB. It has been shown to work best on patients with "true" left bundle branch block (LBBB) where the block is due to disease within the conduction system (and not for example left ventricular hypertrophy or scars). Even if the patient is an ideal candidate for BiV pacing it can sometimes be difficult to achieve the best mechanical resynchronization because of anatomic difficulties, high pacing thresholds or phrenic nerve capture.

In recent years it has been demonstrated that the level of block in true LBBB is often within the bundle of HIS and it is possible in many cases to place a pacing lead distally to the site of block and get capture of both right and left bundles thereby "correcting" the BBB and achieve a normal or near-normal QRS complex. If the conduction system is intact distal to the block this mode of pacing leads to complete resynchronization of the ventricles. HIS-pacing can be achieved as either selective HIS-capture where it is only the conduction system that is paced leading to a narrow QRS complex. However, mostly it is achieved with non-selective HIS-capture where both the septal myocardium close to the pacing site and the His-bundle is captured. This leads to a QRS resembling the QRS achieved by selective HIS-capture but preceded by a delta-wave-like deflection which broadens the QRS complex. Since it is only a small part of the septum that is captured early this does not influence the resynchronization of the heart. In some patients HIS-pacing cannot be achieved due to anatomical difficulties that hinders reaching the HIS bundle with the present tools available. In others it is not possible to come distal to the block and recruiting both the left and the right bundle branch.

There is to date no randomized studies between HIS-bundle pacing and BiV pacing in HFrEF patients with LBBB but there are several case reports and retrospective data on successful HIS-bundle pacing in these patients. The present study will randomize 50 patients in a single centre to HIS-pacing or BiV pacing to determine to which extent it is possible to achieve normalization or near-normalization of the QRS with HIS-bundle pacing and what this translates to with regard to symptom relieve, walking distance, echocardiographic measures and N-terminal pro B-type natriuretic peptide (NT-proBNP) levels as compared to BiV pacing. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03614169
Study type Interventional
Source Rigshospitalet, Denmark
Status Recruiting
Phase N/A
Start date September 9, 2018
Completion date December 2019

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03701880 - Early Use of Ivabradine in Heart Failure N/A
Enrolling by invitation NCT03479424 - Home Outpatient Monitoring and Engagement to Predict HF Exacerbation
Completed NCT02113033 - VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients Phase 2
Recruiting NCT03209180 - Immediate Release Versus Slow Release Carvedilol in Heart Failure Phase 4
Completed NCT01922089 - Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients Phase 2
Recruiting NCT03644446 - Bisoprolol Plasma Residual Concentrations in Chronic Heart Failure
Recruiting NCT03746938 - First in Humans to Evaluate Collagen Patches With Stem Cells in Patients With Ischemic Left Ventricular Dysfunction Phase 1
Not yet recruiting NCT03213821 - Safety and Efficacy of High Protein Diet Versus GFR Based Protein Diet in Heart Failure Patients With Renal Insufficiency N/A
Not yet recruiting NCT03332888 - Safety of HMA-CD20 in Patients With HFrEF Phase 2
Recruiting NCT03141567 - LYmphangiogenesis FacTors in Heart Failure States
Recruiting NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Recruiting NCT03235700 - Hyperemic Efficacy of IV Adenosine in HFrEF N/A
Recruiting NCT03198585 - Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction Phase 2
Enrolling by invitation NCT03574857 - Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance Phase 4
Not yet recruiting NCT03551756 - Assessment of Biomarkers in Patients With Decompensated Heart Failure and Underlying Coronary Artery Disease
Recruiting NCT03816306 - Six Months Clinical and Echocardiographic Outcome of ARNI LCZ696 Therapy in HFrEF Patients
Recruiting NCT03136029 - Exercise and NO in HFrEF Early Phase 1
Withdrawn NCT03119623 - Comparing ARNI With ACE Inhibitor on Endothelial Function Phase 4
Recruiting NCT03061747 - Multi-centre Observational Registry on Patients With Implantable Devices Remotely Monitored N/A
Recruiting NCT03317314 - Cardiopulmonary Interactions in Patients With Heart Failure N/A